ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

KarMMa-3 Is the Only Phase 3 BCMA CAR T Trial to Exclusively Study a Triple-Class Exposed* Population1,2

KarMMa-3 select patient demographics and baseline characteristics1,3

Patients received ABECMA across a dose range of 175 to 529 x 106 CAR-positive T cells (median dose: 445 x 106 CAR-positive T cells)1

safety_nt_left-image safety_nt_left-image

95% (242/254) of KarMMa-3 patients were daratumumab refractory.3

Patients who have received an immunomodulatory agent, a PI, and an anti-CD38 monoclonal antibody.1

Triple-refractory is defined as refractory to at least one immunomodulatory agent, one PI, and one anti-CD38 antibody.3

Derived ISS was calculated using baseline values of albumin and β2-microglobulin. Revised ISS was derived using baseline ISS stage, cytogenetic abnormality, and serum lactate dehydrogenase.3

High-risk cytogenetic abnormalities included del(17p), t(4;14), and t(14;16).3

A high tumor burden was defined as ≥50% CD138-positive plasma cells in bone marrow.3

ISS=International Staging System.

Learn more about the
efficacy and safety of ABECMA

Start the ABECMA
process faster
than ever
—find a certified
treatment center near